Esophagus, Phase III
A Phase 3, Double-blind, Randomized Study of Zolbetuximab in Combination With Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in Participants Whose Tumors Are HER2-negative, Claudin (CLDN) 18.2-positive and Programmed Death-ligand 1 (PD-L1)-Positive
Volunteers
Health Professionals
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Allison Campbell, MD, PhD
- Andrea Brennan
- Armand Russo, MD
- Bruce A. McGibbon, MD
- Clarice Grens
- Daniel Hicks, MD
- Jacquelyne Gaddy, MD, MSc, MSCR
- James Laird, MD
- Jeremy Kortmansky, MD
- Jill Lacy, MD
- Justin Persico, MD
- Kevin Du, MD, PhD, MSCI
- Kimberly L. Johung, MD, PhD
- Kristen Hoxie
- Megan Shulman
- Michael Cecchini, MD
- Neal Fischbach, MD
- Pamela L. Kunz, MD
- Sara Anastasio, RN
- Teresa White
- Thejal Srikumar, MD, MPH
- Vanna Dest
- Virginia Syombathy
- Yifei Zhang, MD
- Last Updated12/06/2025
- Study HIC#2000039866